Skip to main content

Orexigen Therapeutics, Inc. Investor Investigation Concerning 70% Stock Drop

  • If you are a current long term investor of Orexigen Therapeutics, Inc. (NASDAQ:OREX) and/or if you have any information relating the investigation, you have certain options and you should contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this case, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Site Members can sign up for company wide alerts

Investigation Overview

After Orexigen Therapeutics announced on February 1 that the FDA rejected the weight loss drug Contrave an investigation for investors in Orexigen Therapeutics, Inc. (NASDAQ:OREX) shares over possible breaches of fiduciary duties was announced. The investigation by a law firm concerns whether any insider or director or officer has breached their fiduciary duties by taking advantage of...



You must register (for free) or login to view the entire investigation.